TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27796035
Drug: Simple medication
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple medication plan with standard information
Study: 23273975
Drug: Glyburide therapy
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide therapy (dose of 3.3±2.1 mg/day for R230C vs 6.3±5 mg/day for R230R)
Study: 11290867
Drug: Ifosfamide 1500
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 1500 mg/m2 in 1000 ml saline infused over 60 min, mesna 20% of total dose of ifosfamide in three doses for 3 days, mitoxantrone 12 mg/m2 on day 1; treatment repeated every 4 weeks for up to six cycles.
Study: 2682243
Drug: Intravenous desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desmopressin (0.3 microgram per kilogram of body weight)
Study: 31783161
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) mediated antimicrobial photodynamic therapy (aPDT) along with scaling and root planing (SRP)
Study: 31293563
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose 27,476 IU
Study: 24348029
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration (WBV) at 30 Hz and 3.2 g for 5 minutes, three times per week for 6 months
Study: 22186118
Drug: Mildronate 100
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate 100 mg
Study: 22186118
Drug: Mildronate 300
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate 300 mg
Study: 22186118
Drug: Mildronate 1000
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate 1000 mg
Study: 22186118
Drug: Mildronate 3000
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate 3000 mg
Study: 16504757
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy (Arm A): 500 mg/m2 5-fluorouracil, 12 mg/m2 mitoxantrone, and 500 mg/m2 cyclophosphamide with concomitant radiotherapy (50 Gy +/- 10-20-Gy boost)
Study: 16504757
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy followed by radiotherapy (Arm B): 500 mg/m2 5-fluorouracil, 60 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide with subsequent radiotherapy
Study: 11967036
Drug: AM3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM3 (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Study: 11967036
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Study: 10754365
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg i.v. erythromycin
Study: 6788400
Drug: i.v. encainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. encainide 75 mg
Study: 6788400
Drug: oral encainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral encainide 75 mg
Study: 29193211
Drug: TXA 1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 1g intravenous bolus followed by continuous infusion of TXA 1g over 8 hours
Study: 24993769
Drug: Noradrenaline (0-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (0-12 µg/min)
Study: 24993769
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenous bolus six-hourly)
Study: 20032699
Drug: Dexmedetomidine (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6, 1.2, 2.4 ng/ml)
Study: 20032699
Drug: Propofol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1, 2, 4 microg/ml)
Study: 15957828
Drug: Purified Xuefu
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Xuefu Capsule (PXC) with conventional western medicine
Study: 9872814
Drug: Inhaled PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled PGE2 (100 microgram)
Study: 7312535
Drug: Biological content
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological content presented at variable rates
Study: 31995813
Drug: Modafinil (single-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (single-dose, 200 mg)
Study: 31283407
Drug: Myeloid-style consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloid-style consolidation chemotherapy (ADE and MAE)
Study: 31283407
Drug: Lymphoid-style consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoid-style consolidation chemotherapy (IB)
Study: 24126178
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g of milled flaxseed daily for 6 months)
Study: 24126178
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily ingestion of placebo for 6 months)
Study: 12445026
Drug: V11294A (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: V11294A (300 mg)
Study: 7009887
Drug: Trimethoprim-sulfamethoxazole combination
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole combination
Study: 27050206
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus chemotherapy (procarbazine, CCNU, and vincristine)
Study: 23688162
Drug: 0.5% nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% nifedipine cream
Study: 21173378
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by either surgery or chemoradiotherapy
Study: 17368645
Drug: Glucose-boosted saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-boosted saline solution (5% glucose)
Study: 16379581
Drug: Traxoprodil (CP-101,606)
Normalized name: CP
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil (CP-101,606) 72-hour infusion
Study: 11917251
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1% aqueous extract of Fucus vesiculosus, applied twice daily for five weeks
Study: 9637644
Drug: 5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/kg oral clonidine (clonidine group, n=25)
Study: 28421779
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (0.5 g/kg/day)
Study: 26329749
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg/day for 5 years
Study: 26329749
Drug: Telbivudine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine after lamivudine 100 mg/day for 2 years
Study: 21545506
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cyclosporin emulsion once daily (group A)
Study: 21545506
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cyclosporin emulsion twice daily (group B)
Study: 18840643
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (670-2003 mg/d)
Study: 18840643
Drug: Other serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other serum hormone levels
Study: 18840643
Drug: Biomarkers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarkers of bone metabolism, habitual physical activity, habitual calcium intake, and physical fitness
Study: 9188109
Drug: 0.2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg.kg‐1 nasally
Study: 9188109
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 rectally
Study: 9188109
Drug: 0.2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg.kg‐1 sublingually
Study: 9188109
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (nasal, rectal, sublingual)
Study: 2964215
Drug: Sufentanil (0.05-0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.05-0.15 μg/kg)
Study: 2964215
Drug: Diazepam (0.05-0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.05-0.15 mg/kg)
Study: 26784973
Drug: Resveratrol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 1.5 g daily for 6 months
Study: 23731362
Drug: 1,200-mg oral-N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200-mg oral-N-acetylcysteine (NAC) two times a day, starting 48 hours before and up to 72 hours after surgery
Study: 23731362
Drug: 1,200-mg oral-N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200-mg oral-N-acetylcysteine (NAC)
Study: 17011327
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg every 4 weeks (group 1)
Study: 15233305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs (O, R, H, Z)
Study: 11198725
Drug: Placebo (demulcent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (demulcent lozenge without active drug)
Study: 8363681
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg initial dose, repeat 100-200 mg at 2 hours)
Study: 8363681
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg bite and swallow every hour up to 20 mg total)
Study: 24844271
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once daily for 24 weeks
Study: 10655908
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (2.5 micrograms kg‐1 min‐1)
Study: 8542050
Drug: benazepril/hydrochlorothiazide, 20/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril/hydrochlorothiazide, 20/25 mg
Study: 8542050
Drug: benazepril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril, 20 mg
Study: 8542050
Drug: hydrochlorothiazide, 25
Normalized name: HydroCHLOROthiazide, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide, 25 mg
Study: 8263299
Drug: T.O.M. ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: T.O.M. ointment containing oestradiol; applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Study: 8263299
Drug: Ointment without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment without oestradiol (non-treated group); applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Study: 3986167
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 200 mg of progesterone
Study: 3986167
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 400 mg of progesterone
Study: 3986167
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 400 mg of progesterone (compared to placebo)
Study: 31899564
Drug: Counseling +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling + Nicotine Replacement Therapy (C + NRT)
Study: 30115484
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil PCA (40 μg bolus on demand with a 2 min lockout)
Study: 30115484
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (100 mg every 4 h, up to 400 mg in 24 h)
Study: 27537587
Drug: propofol/remifentanil/DEX with
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol/remifentanil/DEX with loading dose (PRDw)
Study: 27537587
Drug: propofol/remifentanil/DEX without
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol/remifentanil/DEX without loading dose (PRDo)
Study: 27537587
Drug: propofol/remifentanil/Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol/remifentanil/Ringer solution (PRR)
Study: 20434110
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg atracurium
Study: 20434110
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg succinylcholine
Study: 6338682
Drug: Postsynaptic alpha‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postsynaptic alpha‐adrenoceptor blockade (prazosin, 2 mg orally)
Study: 6338682
Drug: Combined postsynaptic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined postsynaptic alpha‐ and non‐selective beta‐adrenoceptor blockade (labetalol, 200 mg orally)
Study: 29268598
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (15 mL)
Study: 30041771
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) added to conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Study: 30041771
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Study: 17080429
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (creatine monohydrate, coenzyme Q(10), and lipoic acid)
Study: 9458917
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (transdermal patch, approximately 0.1 mg/day)
Study: 9458917
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion (3% NaCl)
Study: 9156817
Drug: Dextran‐40 based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran‐40 based preservation solution (Dex‐PS)
Study: 23768947
Drug: Existential Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existential Behavioural Therapy (EBT) with mindfulness training
Study: 11242723
Drug: Benzocaine 20%
Normalized name: BENZOCAINE 20% GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine 20% oral adhesive (Orabase-B)
Study: 11242723
Drug: Benzocaine 20%
Normalized name: BENZOCAINE 20% GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine 20% gel (Hurricaine)
Study: 11242723
Drug: EMLA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 5% oral adhesive (EMLA 5% cream in Orabase Plain)
Study: 9140802
Drug: Nebivolol 10
Normalized name: nebivolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 10 mg once daily
Study: 8274289
Drug: 0.0/0.2% isoquinoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0/0.2% isoquinoline in white vaseline/lanette wax cream
Study: 8274289
Drug: 0/10% tannic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0/10% tannic acid in lanette wax cream
Study: 29176391
Drug: Average on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average on-treatment SBP less than 142 mmHg (lowest tertile)
Study: 20500867
Drug: Mandatory second
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandatory second look surgery with CRS and HIPEC (intraperitoneal oxaliplatin with concurrent systemic 5-fluorouracil and leucovorin)
Study: 16817817
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous combined HRT (1 mg 17beta oestradiol and 0.5 mg norethisterone acetate)
Study: 1628373
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 125 mg MPN
Study: 1628373
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 125 mg MPN
Study: 6432200
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg naftidrofuryl, twice daily infusions
Study: 6432200
Drug: 4% dextrose
Normalized name: Clinimix 8/14 Sulfite Free, Amino Acids 8% with 14% Dextrose (Clinimix Sulfite-Free) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% dextrose and saline infusion (control)
Study: 29182791
Drug: Aprepitant 80
Normalized name: aprepitant 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg/day for 7 days plus standardized topical treatment (moderately strong steroid and moisturizer)
Study: 29182791
Drug: Standardized topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized topical treatment alone (control group)
Study: 24762381
Drug: Aqueous oxygen
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous oxygen peroxide (AOP) treatment
Study: 22352336
Drug: Darunavir/ritonavir (DRV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (DRV/r) 800/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Study: 22352336
Drug: Atazanavir/ritonavir (ATV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/r) 300/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Study: 12392804
Drug: Series of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Series of treatment-related videos
Study: 7672157
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d of vitamin E
Study: 2123160
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate (n = 21)
Study: 2123160
Drug: Subcutaneous buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buserelin acetate (n = 19)
Study: 464030
Drug: Myofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofeedback therapy
Study: 30629728
Drug: Active intranasal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intranasal neurostimulation
Study: 30629728
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control intranasal stimulation
Study: 21255134
Drug: ximelagatran (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran (higher doses)
Study: 21255134
Drug: ximelagatran (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran (lower and higher doses)
Study: 21255134
Drug: aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin alone
Study: 17696035
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (LILT) with infrared laser (780 nm, 70 mW, 10 s, 89.7 J/cm2), applied twice a week for four weeks.
Study: 2681451
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg b.i.d. for three months
Study: 799991
Drug: Flurbiprofen 80
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 80 mg/day
Study: 799991
Drug: Flurbiprofen or
Normalized name: flurbiprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen or Ibuprofen
Study: 31150356
Drug: Curcuminoid extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoid extract 250 mg, four times a day on postoperative days 1-3
Study: 29224209
Drug: 9-month course
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month course of daily isoniazid (9H)
Study: 29224209
Drug: 12-week course
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week course of weekly isoniazid and rifapentine (3HP)
Study: 29224209
Drug: 3HP (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP (12-week course of weekly isoniazid and rifapentine)
Study: 29224209
Drug: 9H (9-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9H (9-month course of daily isoniazid)
Study: 21125277
Drug: Aprepitant 125/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125/80 mg group (125 mg on day 1 and 80 mg on days 2-5) and dexamethasone (6 mg on day 1 and 4 mg on days 2 and 3)
Study: 21125277
Drug: Aprepitant 40/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 40/25 mg group (40 mg on day 1 and 25 mg on days 2-5) and dexamethasone (8 mg on day 1 and 6 mg on days 2 and 3)
Study: 19275475
Drug: Vidnar group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidnar group (mobile narrative on a mobile phone during daily train trip)
Study: 16951398
Drug: Neomycin (660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (660 mg three times daily for three consecutive days, starting 2 days before chemotherapy)
Study: 11460274
Drug: Tablet fluoride
Normalized name: sodium fluoride Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet fluoride (0.25 mg F daily)
Study: 11460274
Drug: Liquid fluoride
Normalized name: sodium fluoride Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid fluoride (0.25 mg F daily)
Study: 3980272
Drug: Maintenance MeCCNU
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance MeCCNU + 5‐FU chemotherapy (21 patients)
Study: 3980272
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (30 patients)
Study: 27105046
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (rosuvastatin 10 mg)
Study: 27105046
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy group (rosuvastatin 2.5 mg)
Study: 22337533
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone therapy (ever vs. never)
Study: 11174502
Drug: Prolonged antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antenatal betamethasone therapy (three or more sets of weekly injections given in 21.3% of cases, and > or =4 sets in 12.3% of cases)